Compliance intelligence · Sterile 503A

A second set of eyes on every batch you release.

Archon checks each sterile lot against the governing USP chapters, your state board rules, and your own SOPs, before you compound and before you release. It surfaces what needs a pharmacist's attention and keeps a permanent, cited record.

Request a Demo → Watch the walkthrough 30 minutes · No setup required
Release Review · LOT-2026-0417 LIVE
EM action-level excursion
USP <797> · Buffer area, fill window
CHECKING…
Sterility test pending
USP <71> · Day 9 of 14-day incubation
CHECKING…
Endotoxin within limit
USP <85> · Result on file
CHECKING…
Batch size vs. demand
FD&C §503A · Anticipatory allowance
CHECKING…
Beyond-use date assignment
USP <797> · Category 2, verified
CHECKING…
Reconciling evidence streams…
Illustrative example. Not a real facility, lot, or client record.
Scroll
01 The Problem

The risk lives in the release.
And a release is assembled over fourteen days, not signed in a moment.

A single sterile lot release can turn on a dozen independent signals: sterility and endotoxin results, environmental and personnel monitoring, equipment status, the compounding record, open deviations. Each is governed by a different USP chapter or state rule and lives in a different system, and the evidence does not arrive together. One pharmacist holds it all under time pressure. The room for error is built into the structure of manual review.

Day 0 · At the bench
Compound & fill
EM & PM in control during the fill window. Compounding record, yield, visual inspection, labeling.
Days 1–14 · Off site
Quarantine & incubate
Lot held while USP <71> sterility runs at the third-party lab. The compliance file goes quiet for up to two weeks.
Day ~14 · Release
Reconcile & sign
Sterility & endotoxin return. The pharmacist reconciles every stream, generated days apart, and releases from quarantine.
How it goes wrong
A missed link
An environmental excursion in the buffer area is never connected to the lot filled in that same window.
How it goes wrong
An early release
A sterility test treated as done at Day 7 of a 14-day USP <71> incubation. The product moves anyway.
How it goes wrong
A lapsed record
A balance used while its calibration had expired between compounding and review. Found at inspection.
Archon holds the case open. Each stream is checked as it lands and re-checked as the picture changes. When the last result arrives, the full reconciliation is already assembled for your pharmacist, with every basis cited.
02 The Landscape

Under revised USP <797>, the bar just went up.

The compounding chapters were significantly revised effective November 2023. In the first year of inspections under them, the most-cited 503A findings are records and conditions, not chemistry.

0%
cited for equipment calibration and maintenance, the single most-cited 503A deficiency.
0%
cited for safe storage, labeling, and handling of preparations and materials.
0%
cited for shipping system validation, a growing area for mail-order sterile product.
0%
had no adequately designated Designated Person, the role USP now requires to own quality oversight.

In the first year under the revised chapters, roughly 27% of sterile pharmacies were not fully compliant with Master Formulation Record requirements and ~24% had incomplete cleanroom certification reports. The most-cited failures are record and traceability problems, which is exactly what a cited, permanent release record is built to prevent.

Sources: ACHC / PCAB 2024 Surveyor Quality Review (citation rates) · NABP Verified Pharmacy Program, 213 inspections Nov 2023–Oct 2024 (first year of revised USP <797>).

03 What Archon Is

A safety net across the batch, not just the final sign-off.

Archon starts before a gram is weighed and stays with the lot to release. It runs the go/no-go checks up front, verifies each data stream as it lands across the days the lot is in quarantine, and hands your pharmacist one consolidated, cited report at the gate.

01
Before you compound
Go / no-go: SOPs, operator, equipment, room in control.
02
As evidence lands
Each stream checked across the release window.
03
At the release gate
One cited report for your pharmacist.
04
On the record
Timestamped, attributed, inspection-ready.

Your pharmacist and Designated Person hold the authority on every release decision.

04 See It Run

Watch it work, before you compound and at release.

Two short looks at how Archon sits inside a compounding pharmacy and a hospital pharmacy, then the full walkthrough of the product itself.

The full walkthrough

Best with sound on.

05 How It Works

Three rulebooks: the floor, the patchwork, and your own.

Tier 1 · The Floor
USP <797> and <800>
The compendial standards for sterile compounding and hazardous drug handling that every sterile 503A is held to. Each result cites the exact chapter section.
Tier 2 · The Patchwork
Your state boards, plus the NABP baseline
Every state you ship to is a different rulebook. Archon layers the states you are licensed in onto the NABP-accredited baseline and flags where a lot or shipment meets a state-specific rule.
Tier 3 · Your Own
Your SOPs, read into reviewable rules
Archon drafts candidate rules from your documents. Nothing becomes active until your Designated Person approves it. Archon suggests; your team decides.

Every check resolves to a pass or a flag. A flagged item is then marked critical, which blocks release, or advisory, which needs a pharmacist's review.

PASS
Requirement met. Recorded for the file.
FLAG · ADVISORY
Needs a pharmacist's attention before release.
FLAG · CRITICAL
An issue to resolve, with the basis shown.
06 Archon In Review

What your pharmacist sees before release.

An illustrative release review for a sterile injectable, built from the highest-signal 503A findings. Archon surfaces each item with the chapter or rule it relates to. The pharmacist decides how to proceed.

0%
of reconstructed failure scenarios were flagged before the point of release in testing: real sterile-compounding failures rebuilt from public FDA warning letters and recall notices, including recent peptide and GLP-1 sterility cases.
Public record
Every scenario built only from FDA warning letters and recall notices on the public record. Illustrative of capability, not a claim about any specific facility.
Release Review LOT-2026-0417 · Sterile Injectable
Day ~14 · Release Gate
● FLAG · CRITICAL
EM Action-Level Excursion USP <797>
An EM action level was exceeded in the buffer area during this lot's fill window. The excursion investigation is not yet closed.
Required: excursion investigation closed with product impact assessment.
● FLAG · CRITICAL
Sterility Test Pending USP <71>
The 14-day sterility test is still incubating. No result is on file for this lot yet, so release is blocked.
Required: sterility result on file before release.
● FLAG · CRITICAL
Lapsed Operator Qualification USP <797>
The assigned operator's media-fill qualification lapsed before the recorded date of compounding.
Required: valid media-fill qualification confirmed as of the compounding date.
● FLAG · CRITICAL
Yield Out of Range USP <797> MFR
Recorded yield falls outside the expected range for this batch size, with no investigation attached.
Required: yield deviation investigated and documented.
◐ FLAG · ADVISORY
Batch Size vs. Demand FD&C §503A
Batch size exceeds prescriptions on hand plus the anticipatory allowance. Confirm patient-specific demand.
Recommended: pharmacist confirms patient-specific demand.
Illustrative scenario. Representative of typical USP <797> release findings, not a specific facility, product, or lot.
07 Why A General AI Tool Is Not Enough

Close enough is not good enough in a cleanroom.

01
It makes things up.
General models hallucinate requirements and invent citations. In a regulated release, a confident wrong answer is worse than no answer.
02
It is not consistent.
Ask the same question twice and you can get two answers. A release decision needs a result you can reproduce and defend.
03
It cannot read your data.
A chat tool does not reconcile live records across your compounding software, the lab portal, environmental and personnel monitoring, equipment, and training. That reconciliation is the actual job.
04
It leaves no usable record.
A conversation is not an audit record tied to a specific release. It will not hold up in an inspection.
Archon is built the opposite way: its checks are deterministic, not generative. Every result ties to the exact requirement and to your own data, is consistent each time, and is preserved as a record you can show an inspector.
Your Systems Of Record
Document after the fact
Your compounding software and QMS record what was submitted, not whether it met the requirement at the moment of release.
AI Assistants
Answer questions
Chat tools help with questions but leave no release record tied to a specific lot.
Consultants
Help periodically
Expert advisors and audit-prep firms add real value, but they are not present at every release.
Archon
At the release gate
Ties every result to the exact requirement, surfaces it before release, and preserves the record. Configured to your facility.
08 Built For Trust

Inspection ready, by design.

§
Cited basis
Every result links to the governing USP chapter, state rule, your procedure, or the source condition behind it.
≡
Consistent results
The same submission with the same evidence produces the same outcome, every time.
✓
Designated Person attribution
Every release is attributed to the authorized reviewer, the named role USP <797> now requires to own quality oversight.
∞
Permanent history
What was checked, who acted, and why is preserved with the case as a timestamped, attributed record.

Shaped with input from Board Certified Sterile Compounding pharmacists.

09 Return On Prevention

What one miss can cost.

A Warning Letter
$250K to $5M+
in remediation, consultants, and corrective work. Pending operations are frozen until it is resolved.
A Recall
$1M to $10M+
per event, depending on scope. Roughly half is lost business, not the recall logistics.
Losing 503A Status
Existential
Operate outside 503A conditions and your product becomes an unapproved, misbranded drug. Operations can halt.

Catching one issue before release avoids costs that dwarf any investment in prevention.

The field exists because of the 2012 NECC tragedy: 64+ lives lost, ~751–798 sickened, bankruptcy and a $200M settlement. Sources: industry recall analyses · FDA enforcement filings · NECC bankruptcy record.

10 How Archon Fits

Works with your stack. You would barely know it is there.

Archon reads from what you already run.

Start
Running on day one
Begin with a short onboarding that maps your systems and a structured upload, before any deep integration. You see value immediately, with no change to how you compound.
Integrate
Connect over time
Connections to your compounding software, lab portal, and the rest replace the manual steps as you are ready, on your schedule.
Fit
Shaped to your site
Configured to your terminology, roles, and procedures. Fully managed, so we host and maintain it.

Archon runs beside your existing systems and adds the review and record layer. It checks on the side, surfaces what matters, and does not slow your team down or ask you to replace anything.

11 Team & Advisor

Engineering depth, guided by real facility experience.

NB
Nihaal Bhojwani
Co-Founder
Previously a machine learning researcher at Caltech, with earlier work at NASA and Lockheed Martin. Computer science at the University of Maryland. Builds AI for high-stakes, safety-critical systems.
SK
Saumit Kale
Co-Founder
Computer science at the University of Maryland. Previously at AWS and Varda Space Industries, and built a production rules engine at Citi. Ships reliable software for demanding, high-reliability environments.
Advisor
Amy Summers, PharmD, BCSCP
Amy Summers, PharmD, BCSCP is an independent consultant, specializing in business, operations, quality assurance, and regulatory compliance matters for the pharmaceutical compounding industry. She earned her PharmD degree from the University of California San Francisco and was among the first pharmacists in the nation to earn a Board Certified Sterile Compounding Pharmacist (BCSCP) credential. Dr. Summers has spent her entire career as a pharmacist in various settings centered around non-sterile and sterile compounding. She has formerly served as Director of Operations and Pharmacist in Charge at organizations engaged in compounding and also as Managing Director of a FDA-registered 503B outsourcing facility. With extensive experience in USP standards, accreditation, cGMP, and regulatory compliance, Dr. Summers has also served as an expert witness for matters related to compounding.

See Archon against your own release.

A private walkthrough built around your sterile release workflow. Every requirement checked, every step recorded, every decision your pharmacist's.

Request a Walkthrough → 30 minutes · hello@getarchon.ai